Self-management interventions for people with chronic obstructive pulmonary disease.
Schrijver J, Lenferink A, Brusse-Keizer M, Zwerink M, van der Valk PD, van der Palen J, Effing TW.
Cochrane Database Syst Rev. 2022 Jan 10;1(1):CD002990. doi: 10.1002/14651858.CD002990.pub4.
Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease.
Lange P, Celli B, Agustí A, Boje Jensen G, Divo M, Faner R, Guerra S, Marott JL, Martinez FD, Martinez-Camblor P, Meek P, Owen CA, Petersen H, Pinto-Plata V, Schnohr P, Sood A, Soriano JB, Tesfaigzi Y, Vestbo J.
N Engl J Med. 2015 Jul 9;373(2):111-22. doi: 10.1056/NEJMoa1411532.
Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease.
Walters JA, Tan DJ, White CJ, Gibson PG, Wood-Baker R, Walters EH.
Cochrane Database Syst Rev. 2014 Sep 1;2014(9):CD001288. doi: 10.1002/14651858.CD001288.pub4.
Ciclesonide.
Reynolds NA, Scott LJ.
Drugs. 2004;64(5):511-9; discussion 520-1. doi: 10.2165/00003495-200464050-00005.
Real-world biologics response and super-response in the International Severe Asthma Registry cohort.
Denton E, Hew M, Peters MJ, Upham JW, Bulathsinhala L, Tran TN, Martin N, Bergeron C, Al-Ahmad M, Altraja A, Larenas-Linnemann D, Murray R, Celis-Preciado CA, Al-Lehebi R, Belhassen M, Bhutani M, Bosnic-Anticevich SZ, Bourdin A, Brusselle GG, Busby J, Canonica GW, Heffler E, Chapman KR, Charriot J, Christoff GC, Chung LP, Cosio BG, Côté A, Costello RW, Cushen B, Fingleton J, Fonseca JA, Gibson PG, Heaney LG, Huang EW, Iwanaga T, Jackson DJ, Koh MS, Lehtimäki L, Máspero J, Mahboub B, Menzies-Gow AN, Mitchell PD, Papadopoulos NG, Papaioannou AI, Perez-de-Llano L, Perng DW, Pfeffer PE, Popov TA, Porsbjerg CM, Rhee CK, Roche N, Sadatsafavi M, Salvi S, Schmid JM, Sheu CC, Sirena C, Torres-Duque CA, Salameh L, Patel PH, Ulrik CS, Wang E, Wechsler ME, Price DB; ISAR LUMINANT Working Group.
Allergy. 2024 Oct;79(10):2700-2716. doi: 10.1111/all.16178. Epub 2024 Jun 22.
Associations of pre-COPD indicators with lung function decline and their longitudinal transitions.
Fan J, Cong S, Zhang Y, Jiang X, Wang N, Fang L, Chen Y.
Pulmonology. 2025 Dec 31;31(1):2486881. doi: 10.1080/25310429.2025.2486881. Epub 2025 May 12.
Adjunctive N-Acetylcysteine and Lung Function in Pulmonary Tuberculosis.
Wallis RS, Sabi I, Lalashowi J, Bakuli A, Mapamba D, Olomi W, Siyame E, Ngaraguza B, Chimbe O, Charalambous S, Rachow A, Ivanova O, Zurba L, Myombe B, Kunambi R, Hoelscher M, Ntinginya N, Churchyard G.
NEJM Evid. 2024 Sep;3(9):EVIDoa2300332. doi: 10.1056/EVIDoa2300332. Epub 2024 Aug 27.
Reference values of the provocative concentrations of methacholine that cause 6% and 20% changes in forced expiratory volume in one second in a normal population.
Malo JL, Pineau L, Cartier A, Martin RR.
Am Rev Respir Dis. 1983 Jul;128(1):8-11. doi: 10.1164/arrd.1983.128.1.8.
The effect of nebulized N-acetylcysteine on the phlegm of chronic obstructive pulmonary disease: the NEWEST study.
Rhee CK, Lim SY, Lee WY, Jung JY, Park YB, Lee CY, Hwang YI, Song JW, Choi WI, Yoo KH, Kim KU, Kim YI, Kim TH, Park SJ, Shin KC, Um SJ, Yoon HK, Lee HS, Kim DK, Leem AY; Korean Pulmonary Rehabilitation Study Group.
BMC Pulm Med. 2024 Sep 2;24(1):434. doi: 10.1186/s12890-024-03243-y.
History of lung volume reduction procedures.
Marruchella A, Faverio P, Bonaiti G, Pesci A.
J Thorac Dis. 2018 Oct;10(Suppl 27):S3326-S3334. doi: 10.21037/jtd.2018.04.165.
